CC BY-NC-ND 4.0 · Laryngorhinootologie 2019; 98(S 02): S77
DOI: 10.1055/s-0039-1686030
Abstracts
Oncology

MicroRNA-182 and KTN1: Potential Biomarkers for Prognosis in Oral Squamous Cell Carcinoma

LM Mattes
1   Institut für Pathologie, Universitätsmedizin Göttingen, Göttingen
,
BG Weiss
2   Klinik und Poliklinik für Hals-Nasen-Ohren-Heilkunde, Klinikum der Universität München, Ludwig-Maximilians- Universität München, München
,
M Canis
2   Klinik und Poliklinik für Hals-Nasen-Ohren-Heilkunde, Klinikum der Universität München, Ludwig-Maximilians- Universität München, München
,
M Jakob
2   Klinik und Poliklinik für Hals-Nasen-Ohren-Heilkunde, Klinikum der Universität München, Ludwig-Maximilians- Universität München, München
› Author Affiliations
› Further Information
Also available at
 
 

    Introduction:

    MicroRNA (miRNA) recently evolved as potential cancer biomarkers, in particular miRNA-182 is known to hold an oncogenic function in liver, lung and breast cancer. However, to our knowledge the prognostic impact of miRNA-182 in oral squamous cell carcinoma (OSCC) is still unexplored. Therefore, the aim of this study was to investigate the prognostic value of miRNA-182 and its predicted target gene Kinectin 1 (KTN1) in OSCC.

    Methods:

    Expression of miRNA-182 was analyzed in fresh frozen tumor tissue (n = 36) and healthy oral mucosal tissue (n = 17) using semiquantitative real-time PCR. The expression of the target gene KTN1 was detected via immunohistochemistry. Results were validated in a cohort of The Cancer Genome Atlas (TCGA) for OSCC.

    Results:

    miRNA-182 was significantly upregulated in OSCC (RFC = 1.75; p < 0.001). After dividing the data into a subgroup with high and low expression, a significant better survival was observed in an upregulation of miRNA-182 (overall survival (OS): hazard ratio (HR)= 0.19; 95% confidence interval (95% CI)= 0.04 – 0.86; p = 0.016; recurrence free survival (RFS): HR = 0; 95% CI = 0-inf; p = 0.01; progression free survival (PFS): HR = 0.2; 95% CI = 0.06 – 0.68; p = 0.004). Expression of the target gene KTN1 showed a reciprocal impact on the prognosis (RFS: HR = 2.51; 95% CI = 1.02 – 6.17; p = 0.038; PFS: HR = 2.67; 95% CI = 1.16 – 6.16; p = 0.017). Validation in a TCGA-cohort found comparable findings (miRNA-182 OS: HR = 0.48; 95% CI = 0.23 – 0.99; p = 0.043; KTN1 OS: HR = 2.14; 95% CI = 1.04 – 4.4; p = 0.035).

    Conclusion:

    The classification into prognostic groups via analysis of expression rates of miRNA-182 and KTN1 is feasible; hence, miRNA-182 and KTN1 serve as potential prognostic oncologic markers in OSCC.


    #
    Lena M. Mattes
    Institut für Pathologie, Universitätsmedizin Göttingen,
    Robert-Koch-Str. 40, 37077
    Göttingen

    Publication History

    Publication Date:
    23 April 2019 (online)

    © 2019. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

    Georg Thieme Verlag KG
    Stuttgart · New York